Patents by Inventor Ernest J. Mceachern

Ernest J. Mceachern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20230348387
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 2, 2023
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20230174486
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 8, 2023
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY
    Publication number: 20220409589
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: January 13, 2022
    Publication date: December 29, 2022
    Inventors: Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20220213058
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 7, 2020
    Publication date: July 7, 2022
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof
    Patent number: 10913733
    Abstract: The present invention is directed to thiazolyl piperidine compounds of the general structural formula I: which are inhibitors of O-GlcNAcase. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which O-GlcNAcase is involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which O-GlcNAcase is involved.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: February 9, 2021
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ernest J. McEachern, Harold G. Selnick, Yuanxi Zhou
  • CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY
    Publication number: 20200000774
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Application
    Filed: April 10, 2019
    Publication date: January 2, 2020
    Inventors: Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Patent number: 10322111
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: June 18, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Earl Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosario DiFluri
  • GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20180362517
    Abstract: The present invention is directed to thiazolyl piperidine compounds which are inhibitors of O-GlcNAcase. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which O-GlcNAcase is involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which O-GlcNAcase is involved.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 20, 2018
    Applicant: Alectos Therapeutics, Inc.
    Inventors: Ernest J. McEachern, Harold G. Selnick, Yuanxi Zhou
  • Glucocerebrosidase modulators and uses thereof
    Patent number: 10081601
    Abstract: The invention provides compounds for modulating glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 25, 2018
    Assignee: Alectos Therapeutics Inc.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • Glycosidase inhibitors and uses thereof
    Patent number: 9938299
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 10, 2018
    Assignees: ALECTOS THERAPEUTICS, INC., MERCK SHARP & DOHME CORP.
    Inventors: Harold G. Selnick, Kun Liu, Ernest J. McEachern, Ramesh Kaul, Zhongyong Wei, Yaode Wang, Jiang Chang
  • GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF
    Publication number: 20180009761
    Abstract: The invention provides compounds for modulating glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: September 21, 2017
    Publication date: January 11, 2018
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9815861
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 14, 2017
    Assignees: Alectos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Glycosidase inhibitors and uses thereof
    Patent number: 9809537
    Abstract: The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: November 7, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • Glucocerebrosidase modulators and uses thereof
    Patent number: 9796680
    Abstract: The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in treating synucleinopathy, lysosomal storage disease and relevant neurodegenerative disease.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: October 24, 2017
    Assignee: Alectos Therapeutics Inc.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9718854
    Abstract: The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: August 1, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9701693
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: July 11, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • Glycosidase inhibitors and uses thereof
    Patent number: 9695197
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: July 4, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Qun Dang, Harold G. Selnick
  • Glycosidase inhibitors and uses thereof
    Patent number: 9670195
    Abstract: The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: June 6, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Harold G. Selnick
  • GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20170107180
    Abstract: The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 20, 2017
    Inventors: Ernest J. MCEACHERN, David J. VOCADLO, Yuanxi ZHOU, Harold G. SELNICK
  • Permeable glycosidase inhibitors and uses thereof
    Patent number: 9611275
    Abstract: The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 4, 2017
    Assignees: ALECTOS THERAPEUTICS, INC., MERCK SHARP & DOHME CORP.
    Inventors: Harold G. Selnick, Wenping Li, Eric Hostetler, Kun Liu, Ernest J. McEachern, Yuanxi Zhou, Zhongyong Wei, Changwei Mu, Yaode Wang, Jiang Chang